Patents for A61P 35 - Antineoplastic agents (221,099)
07/2008
07/24/2008WO2008087643A2 Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
07/24/2008WO2008087202A1 Triptolide derivatives for use in the treatment of acute myeloid leukemia
07/24/2008WO2008087177A1 Novel semicarbazide and carbonylhydrazide derivatives useful as potassium channel modulators
07/24/2008WO2008087025A2 Specific therapy and medicament using integrin ligands for treating cancer
07/24/2008WO2008086857A1 Triazole derivative as an hsp 90 inhibitor
07/24/2008WO2008086743A1 The application of the extract of antrodia cinnamomea for inhibitting the growth of tumour cell
07/24/2008WO2008086612A1 Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
07/24/2008WO2008086610A1 Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
07/24/2008WO2008070011A3 Combination of an hdac inhibitor and an antimetabolite
07/24/2008WO2008065378A3 Binding members for interleukin-6
07/24/2008WO2008065378A2 Binding members for interleukin-6
07/24/2008WO2008065068A3 Substituted dihydroimidazoles and their use in the treatment of tumors
07/24/2008WO2008060789A3 Use of spiro-oxindole compounds as therapeutic agents
07/24/2008WO2008051808A3 Bicyclic triazoles as protein kinase modulators
07/24/2008WO2008045834A3 Kinase inhibitors
07/24/2008WO2008020269A3 A method of treating tumors with azaxanthones
07/24/2008WO2008005538A3 Methods of using igf1r and abl kinase modulators
07/24/2008WO2007146226A3 Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
07/24/2008WO2007134169A9 Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
07/24/2008WO2007043050A3 Bioconjugates comprising sulfated polysaccharides and their uses
07/24/2008WO2006116107A3 Immunoliposome composition for targeting to a her2 cell receptor
07/24/2008US20080177093 Use of an oxidopyrylium species as an intermediate in a chemical reaction; oxidopyrylium species is generated photochemically from a 3-hydroxychromone derivative followed by 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile
07/24/2008US20080177082 N3 alkylated benzimidazole derivatives as mek inhibitors
07/24/2008US20080177064 Dipeptidyl peptidase inhibitors
07/24/2008US20080176961 Phosphodiesterase acitvity and regulation of phosphodiesterase 1-B-mediated signaling in brain
07/24/2008US20080176959 Biodegradable polyphosphates complex for controlled release of bioactive substances and related methods
07/24/2008US20080176946 Formulations for cancer treatment
07/24/2008US20080176932 Pharmaceutical Compositions Containing Baicalein And Baicalin With Synergistic Effect In Tumor Treatment
07/24/2008US20080176931 e.g. 5,7-Bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-yl 3-(benzyloxy)benzoate; antiproliferative, antitumor agent; reducing tumor cell growth; more potent, better bioavailability than catechin
07/24/2008US20080176927 difimicin and one or more antioxidants, such as butylated hydroxytoluene; substantially increase shelf life; C. difficile-associated diarrhea
07/24/2008US20080176923 particularly cis-hydroxyproline derivatives; inhibit or prevent proliferation, infiltration, invasion, angiogenesis and/or metastasization of cancer cells; 1-methyl-4-phenylaminocarbonyloxyproline ethyl ester; can be use as hybrid molecules or in combined agents; oral bioavailibility; chemical stability
07/24/2008US20080176916 A-amino-n-hydroxy-acetamide derivatives
07/24/2008US20080176906 excellent androgen receptor antagonism, excellent pharmacokinetics; low toxicity; anticarcinogenic agents; 1-{[6-Chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile
07/24/2008US20080176889 4-{2-[Bis-(2-chloroethyl)amino]ethoxy}-10H-acridine-9-one; Anticancer agents
07/24/2008US20080176881 Compounds and compositions as protein kinase inhibitors
07/24/2008US20080176879 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide; for the treatment of allergies and/or systemic matocytosis associated with FIP1L1-PDGFR alpha -gene fusion; platelet derived growth factor alpha inhibitors
07/24/2008US20080176875 Substituted quinazolines
07/24/2008US20080176874 Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same
07/24/2008US20080176872 Chemical Compounds
07/24/2008US20080176866 3-(5-Bromo-2-{4-[5-bromo-4-((1R,2R)-2-hydroxy-1-methyl propylamino)-pyrimidin-2-ylamino]phenylamino}pyrimidin-4-ylamino)butan-2-ol; cell cycle and tyrosine kinase receptor inhibitor; antiproliferative, anticarcinogenic agent
07/24/2008US20080176849 e.g. N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]-amino]methyl]phenyl]-2E-2-propenamide; histone deacetylase inhibitor; anticarcinogenic, antitumor, antiproliferative agents; improved stability
07/24/2008US20080176848 e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders
07/24/2008US20080176847 Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
07/24/2008US20080176846 e.g. 3-(5-amino-2-methylphenyl)-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one; protein kinase inhibitor; antiinflammatory, anticarcinogenic, antiallergen, antidiabetic, antiischemic, hypotensive agent
07/24/2008US20080176841 (amidomethyl-amido)-(carboxy/amido)epoxide derivatives; cathepsin inhibitor; antiinflammatory, anticarcinogenic, antidiabeticagent, antiallergen, autoimmune and neurodegenerative disorders
07/24/2008US20080176840 e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections
07/24/2008US20080176835 Prenyl Transferase Inhibitors
07/24/2008US20080176833 Dihydropyridine derivatives as useful as protein kinase inhibitors
07/24/2008US20080176830 Compounds, Compositions, and Methods
07/24/2008US20080176828 anticarcinogenic agent, synergistic with microtubulin stabilizers, other anticancer agents, vaccines, immunotherapy
07/24/2008US20080176820 Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro
07/24/2008US20080176815 Compounds that interact with kinases
07/24/2008US20080176814 nonpeptidic inhibitors of cathepsin G; genetic diseases, degenerative diseases, DNA damages, neoplasia and/or skin diseases; DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing
07/24/2008US20080176800 Methods for the delivery of bioactive substances with biodegradable polyphosphates
07/24/2008US20080176795 administering human H3 relaxin, carriers, diluents and/or excipients; anxiolytic agents; hormones
07/24/2008US20080176792 Vegfr-1 targeting peptides
07/24/2008US20080176279 HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
07/24/2008US20080176231 Apotosis inducing viral protein, in combination with defective p53 protein, for use in treatment of cell proliferative and autoimmune disorders
07/24/2008US20080175918 Chemically cross-linked elastomeric microcapsules
07/24/2008US20080175895 System, devices, and methods for iontophoretic delivery of compositions including antioxidants encapsulated in liposomes
07/24/2008US20080175892 fullerene carbon nanotube linking to paclitaxel through polyethylene glycol, serinol, succinimidyl-3-(2-pyridyldithio)-propionate or succinic acid; anticarcinogenic agents treating lung cancer; drug target with antibody; aerosols drug delivery
07/24/2008US20080175884 Polymer coatings as carriers for the drug delivery of a methosyaminocarbonyloxy derivative of rapamycin and another drug(s) such as an antiproliferative agent, anticoagulant, etc.; reduces restenosis in vasculature procedures to a level of 0-25%; coronary/periferal stents; grafts ; balloons
07/24/2008US20080175871 Eliciting improved immune responses
07/24/2008US20080175855 Containing one or more epitopes recognized by and binding to a BAT monoclonal antibody; cancer vaccines
07/24/2008US20080175847 Anti-dll4 antibodies and methods using same
07/24/2008US20080175846 Antibodies against cancer antigen tmeff2 and uses thereof
07/24/2008US20080175844 Activin-like receptor kinase immunoglobulin fusion for prevention and treatment of cell proliferative and vision defects; angiogenesis inhibitors
07/24/2008US20080175842 Compositions and methods for treatment
07/24/2008US20080175841 Antagonistic Anti-hTNFSF13b Human Antibodies
07/24/2008US20080175840 Methods for treating angiogenesis related disorders
07/24/2008US20080175828 Proliferated cell lines and uses thereof
07/24/2008US20080175818 Using replication-defective plasmid comprising p53 nucleotide sequences as as delivery tool for antitumor agents
07/24/2008US20080175814 Quinoline derivatives for modulating dna methylation
07/24/2008US20080175789 Prostate specific membrane antigen (PSMA); for diagnosis, detection and treatment of cancer; gene overexpression; kits
07/24/2008DE102007027201A1 Conjugates useful for chemotherapy or positron emission tomography comprising a platinum complex and a glucose compound
07/24/2008DE102007002717A1 Heterocyclische Indazolderivate Heterocyclic indazole derivatives
07/24/2008DE102007002715A1 Triazolderivat Triazole derivative
07/24/2008CA2712073A1 Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
07/24/2008CA2675980A1 Use of dast for treatment of cancers with acquired resistance to kit inhibitors
07/24/2008CA2675979A1 Treatment of cancers having resistance to chemotherapeutic agents
07/24/2008CA2675834A1 Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
07/24/2008CA2675813A1 Specific therapy and medicament using integrin ligands for treating cancer
07/24/2008CA2675737A1 Triazole derivative
07/24/2008CA2675736A1 Composition for treatment of pancreatic cancer
07/24/2008CA2675733A1 Method for glycosylation of flavonoid compounds
07/24/2008CA2675358A1 Inhibitors of mek
07/24/2008CA2674865A1 Indole derivative having i.kappa.b kinase .beta. inhibitory activity
07/24/2008CA2674698A1 New classical antifolates
07/24/2008CA2674589A1 Antiviral nucleoside analogs
07/24/2008CA2674552A1 Vaccine
07/23/2008EP1947119A2 Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
07/23/2008EP1947109A2 Biologically active peptides
07/23/2008EP1947102A1 Compositions comprising diazepinoindole derivatives as kinase inhibitors
07/23/2008EP1946776A1 Stabilized TNFR-Fc composition comprising arginine
07/23/2008EP1946775A2 Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
07/23/2008EP1946770A1 Uses of DC-sign and DC-signr for inhibiting hepatitis C virus infection
07/23/2008EP1946762A1 Scavenger of harmful active oxygen and/or free radical in living body
07/23/2008EP1946758A1 Treatment of acute myeloid leukemia
07/23/2008EP1946749A1 Anti-angionene compositions and methods of use
07/23/2008EP1946748A1 Composition for administration to mammals or humans